ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losartan indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate.switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria.reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary composite end point

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan - losartan - hypertension : losartan is indicated for the treatment of hypertension. heart failure: losartan is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended.

ישראל - עברית - Ministry of Health

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

ישראל - עברית - Ministry of Health

j-c health care ltd - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

ישראל - עברית - Ministry of Health

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

ישראל - עברית - Ministry of Health

j-c health care ltd - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - טבליות מצופות פילם - losartan potassium 50 mg - losartan - losartan - hypertension: losartan is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended. renal protection in type-2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of losartan on the primary deposite endpoi

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - losartan potassium - טבליות מצופות פילם - losartan potassium 12.5 mg - losartan - losartan - hypertension: losartan is indicated for the treatment of hypertension. heart failure: losartan is indicated for the treatment of heart failure (nyha ii) when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losartan is not recommended.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 12.5 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii) , when treatment with an ace inhibitor is no longer considered appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended.